Previous Close | 0.1150 |
Open | 0.1200 |
Bid | 0.1100 x 0 |
Ask | 0.1200 x 0 |
Day's Range | 0.1200 - 0.1200 |
52 Week Range | 0.0800 - 0.1500 |
Volume | |
Avg. Volume | 57,638 |
Market Cap | 14.98M |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0350 |
Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that, as previously announced by the Company in its March 1, 2023 press release, pursuant to the formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”) dated March 2, 2023 amending the terms of the Company’s amended and
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as am
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 01, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Pivot Financial I Limited Partnership (“Pivot”) has agreed, in principle, to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”), by, among other things,